DOCSLIB.ORG

American Rheumatism Association

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
American Rheumatism Association Ann Rheum Dis: first published as 10.1136/ard.15.4.374 on 1 December 1956. Downloaded from Ann. rheum. Dis. (1956), 15, 374. AMERICAN RHEUMATISM ASSOCIATION PROCEEDINGS OF THE ANNUAL MEETING, 1956 The Annual Meeting of the American Rheumatism its membership. These goals were four in number. Association was held at Chicago, Illinois, on June 8 While successfully achieved in part, they bear repetition and 9, 1956, under the presidency of Dr. Charles L. and re-emphasis a decade later, along with additional Short of Boston. Abstracts of 30 papers and the comments provoked by the changing outlook in which we discussions thereon are printed below. One session have all shared on the still elusive search for the cause and cure of the rheumatic diseases. was arranged in conjunction with the American I should like to mention one goal first, perhaps because Council on Rheumatic Fever and Congenital it has been achieved so magnificently and I am sure Heart Disease. Panel Discussions were held on beyond the expectation of the membership 10 years ago. "Gout" (Moderator: Dr. A. Gutman) and on "A This is what Dr. Holbrook modestly called a strengthen- Teaching Collection of Lantern Slides illustrating ing of the work in public relations, with the eventual the Pathology of Arthritis and Rheumatism", the development of a fund-raising organization. Within work of a Sub-committee of the Arthritis and 2 years the Arthritis and Rheumatism Foundation was Rheumatism Foundation (Moderator: Dr. Currier established. In another 2 years, by the combined efforts of the Foundation and our own Association, the National McEwen). A report on "Proposed Diagnostic by copyright. Criteria for Rheumatoid Arthritis" was presented by Institute working in the field of metabolic diseases was expanded to include the field of rheumatism and funds the Committee on Diagnostic Criteria (Chairman: were appropriated by Congress to carry on this aug- Dr. Marian W. Ropes). mented work. We are now blessed with the happy co-operation of professional, voluntary, and govern- PRESIDENTIAL ADDRESS mental groups, all concerned with a common objective, the alleviation and eventual prevention of a group of BY chronic disabling diseases. It is unnecessary to list in detail to this audience the CHARLES L. SHORT contributions made by the Arthritis and Rheumatism Foundation, both nationally and locally, to an improved http://ard.bmj.com/ President of the American Rheumatism Association, 1955-56 outlook for the rheumatic patient, not only at this time, by the education of those concerned with his care, but also The presidential addresses delivered before this in the future, by the financing of clinical and basic association have usually dealt with a clinical or scientific research. To quote just two figures, the amount subject ofspecial interest to the speaker at the time or with expended for such investigations in the United States has broad and general aspects of teaching and research increased from $300,000 yearly in 1948 to $3,000,000 in in the rheumatic diseases. Only a few have considered in 1955. No statistical tests of significance are necessary to some assume an association between this increase and the detail the activities and aims of your association on September 29, 2021 by guest. Protected -subjects with which I have been intimately concerned operations of the Arthritis and Rheumatism Foundation during the past year, and which I wish to discuss this and the National Institute for Arthritis and Metabolic afternoon in a brief and necessarily incomplete form. Diseases. Just 10 years ago, in May, 1946, the American Rheuma- A second major goal set 10 years ago was the education tism Association assembled in New York for what was of physicians in the basic treatment of arthritis. The last aptly termed a Reunion Meeting. During the war years, 6 years' experience with suppressive agents, valuable no meetings had been held and no new members added. as they are in selected cases and as research tools, has The affairs of the society had been in the custodial care failed to diminish the importance of measures generally of the Officers and Executive Committee while the greater believed to be helpful in the management of a disease part of the membership was scattered far and wide in like rheumatoid arthritis. I say "generally believed to be the armed forces. In his presidential address at this helpful", because the value of rest, salicylates, simple meeting, Dr. W. Paul Holbrook, took the opportunity forms of physical therapy, non-operative orthopaedic to present what he called major goals or challenging measures, and above all the study and treatment of the opportunities for accomplishment by the association and patient as a human being, has yet to be established by 374 Ann Rheum Dis: first published as 10.1136/ard.15.4.374 on 1 December 1956. Downloaded from AMERICAN RHEUMATISM ASSOCIATION 375 controlled therapeutic studies. Nevertheless, few of us or even fatal in childhood, geriatrists and pediatricians, would wish to discard such measures, whether or not who are fundamentally internists, should be brought suppressive agents are also used. To supply the practi- into our membership. tioner with the knowledge and will to prescribe these methods in a specific and detailed fashion is no easier task to-day than it was 10 years ago. In addition, we have the obligation of pointing out the proper indications for suppressive treatment, along with warnings against its 1,200T injudicious or unwarranted use. Certainly these objects have begun to appear within closer reach through the 1,000+ educational programme of the Arthritis and Rheumatism (I) I Foundation as related to the practitioner. The Bulletin w and m on Rheumatic Disease, the Primer, the Rheumatism E 800-I- Review, while created by our member, could never have w received their present wide distribution to the medical profession, nor could our exhibits have been financed U- without assistance from the Arthritis and Rheumatism 0 600- cr Foundation. Valuable as these methods are, our w personal contact with the practitioner should provide m opportunity for more vivid and effective forms of D 400- _- instruction. These include not only talks at society z and staff meetings and the careful teaching of trainees and of physicians assisting in arthritis clinics, but 200- _ especially our teaching in regard to diagnosis and patient management as consultants. If the referring physician is given a detailed, conscientiously prepared outline of I the problems presented by an individual patient and 1946 148 1450 1952 1454 1956 their best solution, he should gradually but surely be able YEAR by copyright. to apply what he learns to other cases of rheumatic disease Fig. 1.-Membership of the American Rheumatism Association from encountered in his practice. 1946 to 1956. In 1946, only one local rheumatism society was affiliated with the American Rheumatism Association. This was the New York Rheumatism Association, which The question may be raised whether the general practi- was host to the parent society at the Reunion Meeting. tioner or generalist belongs in the society. I feel that a The third major goal was the organization of affiliated certain number do, along with internists for whom societies "in every community that can support one". rheumatism represents only one facet of their practice. A substantial growth in their number has taken place Such individuals can learn and be stimulated by since then, the present total being 25. Six have been attendance at our meetings, and can also contribute to them by their clinical observations of early and atypical http://ard.bmj.com/ added in the last year, largely through the effective efforts disease and their unique privilege of following certain of the Committee on Affiliation with Local Societies. patients through a lifetime ofpractice. But since there are still 25 states without such a society, I include the radiologist because the clinical members the challenge still lies before us. of our society rely on his skill so often in their diagnoses, The fourth major goal was "a wise and progressive but, as far as I can recall, it is some time since a distinctly enlargement of membership". As shown in Fig. 1, radiological communication has been read at one of our the membership has steadily increased, with a recent meetings. spurt due to the personal efforts of our last year's Orthopaedists are among the founding fathers of the president. We still need more new members representing Society and, in addition to their contributions to recon- on September 29, 2021 by guest. Protected the widely varying interests of those now concerned with the study and treatment of rheumatic disease. The TABLE Table brings out the latter point; the first column lists CLASSIFICATION OF PHYSICIANS AND INVESTIGATORS those whose purpose is to help the rheumatic patient more ENGAGED IN THE STUDY AND TREATMENT OF THE effectively and the second those primarily concerned with RHEUMATIC DISEASES the advancement of knowledge in this field. "Rheumatologist" Clinical Investigator Internist Epidemiologist Pediatrician Biostatistician Most rheumatologists, or rather most internists with a Geriatrist Fundamental Investigator major or substantial interest in musculoskeletal disease, Generalist Biologist Radiologist Biochemist are already among our members. We must be on the Orthopedist Histochemist look-out, however, for additional members from this Physiatrist Biophysicist group, whether younger or older, once it is clear that Psychiatrist Embryologist Military Surgeon Bacteriologist their interests lie in this direction. Industrial Physician Immunologist Since rheumatic disease frequently contributes to dis- Pharmaceutical Physician Pathologist ability in our aging population and may be incapacitating Pharmacologist 7 Ann Rheum Dis: first published as 10.1136/ard.15.4.374 on 1 December 1956. Downloaded from 376 ANNALS OF THE RHEUMATIC DISEASES structive surgery, are often the first to see a patient with over 20 years, has led directly to an attempt to joint disease.
Load more

Recommended publications
  • Rotator Cuff Tendon Ruptures and Degeneration As the First Manifestation of Polymyalgia Rheumatica Disease - a Case Report
    Open Access Austin Journal of Clinical Case Reports Case Report Rotator Cuff Tendon Ruptures and Degeneration as the First Manifestation of Polymyalgia Rheumatica Disease - A Case Report Bazoukis G1*, Michelongona P2, Papadatos SS1, Pagkalidou E1, Grigoropoulou P1, Fragkou A1 and Abstract Yalouris A1 Polymyalgia Rheumatica (PMR) is a common rheumatic disease of the 1Department of Internal Medicine, General Hospital of elderly. Although it is a well-established disease, its causes and pathophysiology Athens “Elpis”, Greece remain unclear. In our case report we present an 83-year-old female presented 2Department of Internal Medicine, General Hospital of at the emergency department because of fever and diarrhea. Her medical Korinthos, Greece history included a recent orthopedic surgery because of tendons rupture of the *Corresponding author: George Bazoukis, rotator cuff. Her blood exams showed increased inflammatory markers and a Department of Internal Medicine, General Hospital of three-digit ESR. The diagnosis of PMR was set after the exclusion of infectious Athens “Elpis”, Greece and other diseases that mimic PMR symptoms. To the best of our knowledge, it is the first time that rotator cuff tendons rupture and degeneration is the first Received: June 05, 2016; Accepted: August 02, 2016; manifestation of PMR disease. Clinicians should be aware of the degeneration Published: September 08, 2016 of the shoulder and hip extra-articular structures in PMR and they should keep in mind that it can be the first manifestation of the disease. Keywords: Polymyalgia rheumatica; Rotator cuff denegeration; Tendon rupture Introduction and infraspinatus muscles as well as significant tendinopathy of the subscapularis and long head of biceps muscles.
    [Show full text]
  • Single Injection May Quell Chronic Plantar Fasciitis
    March 2006 • www.rheumatologynews.com Lupus/CT Diseases 27 Single Injection May Quell Chronic Plantar Fasciitis BY BRUCE JANCIN lief in nine such patients treated in open- try botulinum toxin A because of pub- greater than 4 on a 0-10 visual analog Denver Bureau label fashion. Based upon these highly en- lished reports citing its general analgesic scale. At week 2 this score was halved. At couraging results, a randomized, double- effect and inhibition of inflammatory pain. week 6 it was quartered. The same pattern V IENNA — Botulinum toxin A injection blind, and placebo-controlled clinical trial The nine patients selected for botu- of improvement was noted for maximum shows promise as a novel therapeutic op- is now planned, according to Dr. Placzek linum toxin A injection averaged age 55 pain during the previous 48 hours. tion for chronic plantar fasciitis patients of Charité Hospital, Berlin. years, with a 14-month history of plantar No muscle weakness or other adverse unresponsive to conventional treatments, Most patients with chronic plantar fasci- fasciitis refractory to all standard mea- events were observed, he noted at the Dr. Richard Placzek reported at the annual itis respond to physical therapy, cortico- sures. Follow-up evaluations were con- meeting sponsored by the European European Congress of Rheumatology. steroid injections, orthotics, acupuncture, ducted 2 weeks postinjection and every 1- League Against Rheumatism. Patients in- A single 200-unit injection into the and/or high-energy ultrasound extracor- 3 months thereafter up to 52 weeks. dicated they were satisfied with the pain painful region at the origin of the plantar poreal shock wave therapy.
    [Show full text]
  • The Painful Heel Comparative Study in Rheumatoid Arthritis, Ankylosing Spondylitis, Reiter's Syndrome, and Generalized Osteoarthrosis
    Ann Rheum Dis: first published as 10.1136/ard.36.4.343 on 1 August 1977. Downloaded from Annals of the Rheumatic Diseases, 1977, 36, 343-348 The painful heel Comparative study in rheumatoid arthritis, ankylosing spondylitis, Reiter's syndrome, and generalized osteoarthrosis J. C. GERSTER, T. L. VISCHER, A. BENNANI, AND G. H. FALLET From the Department of Medicine, Division of Rheumatology, University Hospital, Geneva, Switzerland SUMMARY This study presents the frequency of severe and mild talalgias in unselected, consecutive patients with rheumatoid arthritis, ankylosing spondylitis, Reiter's syndrome, and generalized osteoarthosis. Achilles tendinitis and plantar fasciitis caused a severe talalgia and they were observed mainly in males with Reiter's syndrome or ankylosing spondylitis. On the other hand, sub-Achilles bursitis more frequently affected women with rheumatoid arthritis and rarely gave rise to severe talalgias. The simple calcaneal spur was associated with generalized osteoarthrosis and its frequency increased with age. This condition was not related to talalgias. Finally, clinical and radiological involvement of the subtalar and midtarsal joints were observed mainly in rheumatoid arthritis and occasionally caused apes valgoplanus. copyright. A 'painful heel' syndrome occurs at times in patients psoriasis, urethritis, conjunctivitis, or enterocolitis. with inflammatory rheumatic disease or osteo- The antigen HLA B27 was present in 29 patients arthrosis, causing significant clinical problems. Very (80%O). few studies have investigated the frequency and characteristics of this syndrome. Therefore we have RS 16 PATIENTS studied unselected groups of patients with rheuma- All of our patients had the complete triad (non- toid arthritis (RA), ankylosing spondylitis (AS), gonococcal urethritis, arthritis, and conjunctivitis).
    [Show full text]
  • REPETITIVE STRAIN INJURY AWARENESS Tenosynovitis
    REPETITIVE STRAIN INJURY RSIA AWARENESS Tenosynovitis RSI Conditions The term Repetitive Strain Injury is an umbrella term used to describe a number of specific musculoskeletal conditions, including tenosynovitis, as well as ‘diffuse RSI’, which is more difficult to define but which recent research attributes to nerve damage. These conditions are often occupational in origin. Lack of adequate diagnosis or access to appropriate treatment can exacerbate the condition and sometimes leads to job loss and economic hardship. What is Tenosynovitis? Tenosynovitis is the tender swelling of the rope or cord like structures (tendons) which connect muscles to the bones in order to work the joints of the body, and inflammation of the lining of the protective synovial sheath that covers these tendons. Areas most frequently affected are the hand, wrist or arms, although it may occur at any tendon site. De Quervain’s or Stenosing Tenosynovitis results from inflammation or constriction of the tendons on the thumb side of the wrist. A localised swelling affecting the flexor tendons of the hand is known as Trigger Finger. The Symptoms When the gliding surfaces of the tendon and sheath become roughened and inflamed from overuse, tenosynovitis will present as aching, tenderness and swelling of the affected area. There may also be also stiffness of the joint, shooting pains up the arm and creaking tendons (crepitus). The ability to grip can be lost. A localised swelling at the base of the thumb may indicate De Quervain’s. Tenosynovitis can just last a few days, but in some cases may go on for many weeks or even months.
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Review Article
    REVIEW ARTICLE COLLAGEN METABOLISM COLLAGEN METABOLISM Types of Collagen 228 Structure of Collagen Molecules 230 Synthesis and Processing of Procollagen Polypeptides 232 Transcription and Translation 233 Posttranslational Modifications 233 Extracellular Processing of Procollagen and Collagen Fibrillogenesis 240 Functions of Collagen in Connective rissue 243 Collagen Degradation 245 Regulation of the Metabolism of Collagen 246 Heritable Diseases of Collagen 247 Recessive Dermatosparaxis 248 Recessive Forms of EDS 251 EDS VI 251 EDS VII 252 EDS V 252 Lysyl Oxidase Deficiency in the Mouse 253 X-Linked Cutis Laxa 253 Menke's Kinky Hair Syndrome 253 Homocystinuria 254 EDS IV 254 Dominant Forms of EDS 254 Dominant Collagen Packing Defect I 255 Dominant and Recessive Forms of Osteogenesis Imperfecta 258 Dominant and Recessive Forms of Cutis Laxa 258 The Marfan Syndrome 259 Acquired Diseases and Repair Processes Affecting Collagen 259 Acquired Changes in the Types of Collagen Synthesis 260 Acquired Changes in Amounts of Collagen Synthesized 263 Acquired Changes in Hydroxylation of Proline and Lysine 264 Acquired Changes in Collagen Cross-Links 265 Acquired Defects in Collagen Degradation 267 Conclusion 267 Bibliography 267 Collagen Metabolism A Comparison of Diseases of Collagen and Diseases Affecting Collagen Ronald R. Minor, VMD, PhD COLLAGEN CONSTITUTES approximately one third of the body's total protein, and changes in synthesis and/or degradation of colla- gen occur in nearly every disease process. There are also a number of newly described specific diseases of collagen in both man and domestic animals. Thus, an understanding of the synthesis, deposition, and turnover of collagen is important for the pathologist, the clinician, and the basic scientist alike.
    [Show full text]
  • Palindromic Rheumatism Or When Do You Decide to Treat an Asymptomatic Seropositive RA Patient? What Is This?
    Palindromic Rheumatism or When do you decide to treat an asymptomatic seropositive RA patient? What Is This? • 11.15.15 • 56 yo man comes for 2nd opinion for bouts of severe large joint monoarthritis lasting 24 hours or longer. • Vague about duration “10-15 years.” Had wrist synovectomy 2005 after “trauma.” • Saw rheumatologist 2012: ACPA>500, RF 60. • Loss of shoulder motion in all planes. • At the conclusion of this presentation, the participant should be able to: – Appreciate the relationship of Palindromic Rheumatism (PR) and progression to RA – Understand the biology of intercritical PR – Define the utility of prevention strategies – Comprehend the yield of imaging in PR and how it informs PR pathophysiology • Should we try to prevent? How? Annual transition to RA is greater than 15% in which of the following ACPA+ pts? A. Arthralgia B. Arthralgia + Imaging + CRP C. Palindromic Rheumatism D. Asymptomatic Twin E. Interstitial Lung Disease Rheumatoid Arthritis Pathogenesis Tolerance broken-AutoAb appear Adaptive Immune Response Locus and Trigger? Systemic Nature? “Amplification” Synovial Targeting with variable kinetics? Innate vs Adaptive Immunity? Joint Targeting ACPA-IC deposit or are formed de novo in joint? Or something else? Tissue Injury Rheumatoid Arthritis Persistence of the Systemic Trigger? Systemic autoimmunity & inflammation T cells/B Cells Immune Complexes TNF, IL-6, GM-CSF No treatment shown to eliminate systemic process Where does MTX work? Joint Inflammation MF, FLS, Cartilage, Bone RA Centers in Synovium, Destroying All Around It? Why Is Palindromic Rheumatism Palindromic? Systemic inflammation Followed by resolution? e.g. like gout? Why does it resolve? Why does it stop resolving? Single Joint Inflammation Palindromic Rheumatism (PR) • How frequent is PR as an initial presentation of RA? • What is the mechanism of PR? • Is synovitis present during its intercritical phase? • What is the frequency of progression to RA in 5 years? Treatment? Is Palindromic Rheumatism a Common Presentation? Frequency relative to new onset RA is: A.
    [Show full text]
  • Mechanisms of Synthesis of Purine Nucleotides in Heart Muscle Extracts
    Mechanisms of Synthesis of Purine Nucleotides in Heart Muscle Extracts David A. Goldthwait J Clin Invest. 1957;36(11):1572-1578. https://doi.org/10.1172/JCI103555. Research Article Find the latest version: https://jci.me/103555/pdf MECHANISMS OF SYNTHESIS OF PURINE NUCLEOTIDES IN HEART MUSCLE EXTRACTS1 BY DAVID A. GOLDTHWAIT2 (From the Departments of Biochemistry and Medicine, Western Reserve University, Cleveland, Ohio) (Submitted for publication February 18, 1957; accepted July 18, 1957) The key role of ATP, a purine nucleotide, in 4. Adenine or Hypoxanthine + PRPP -> AMP the conversion of chemical energy into mechanical or Inosinic Acid (IMP) + P-P. work by myocardial tissue is well established (1, The third mechanism of synthesis is through the 2). The requirement for purine nucleotides has phosphorylation of a purine nucleoside (8, 9): also been demonstrated in the multiple synthetic 5. Adenosine + ATP -, AMP + ADP. reactions which maintain all animal cells in the Several enzymatic mechanisms are known which steady state. Since the question immediately arises result in the degradation of purine nucleotides and whether the purine nucleotides are themselves in nucleosides. The deamination of adenylic acid is a steady state, in which their rates of synthesis well known (10): equal their rates of degradation, it seems reason- 6. AMP -* IMP + NH8. able to investigate first what mechanisms of syn- Non-specific phosphatases (11) as well as spe- thesis and degradation may be operative. cific 5'-nucleotidases (12) have been described At present, there are three known pathways for which result in dephosphorylation: the synthesis of purine nucleotides. The first is 7.
    [Show full text]
  • Calcium 5'-Ribonucleotides
    CALCIUM 5'-RIBONUCLEOTIDES Prepared at the 18th JECFA (1974), published in NMRS 54B (1975) and in FNP 52 (1992). Metals and arsenic specifications revised at the 57th JECFA (2001). An ADI ‘not specified’ was established at the 18th JECFA (1974). SYNONYMS Calcium ribonucleotides, INS No. 634 DEFINITION Chemical names (Mixture of) calcium inosine-5'-monophosphate and calcium guanosine-5'- monophosphate Chemical formula C10H11CaN4O8P · x H2O and C10H12CaN5O8P · x H2O Structural formula Calcium 5’-guanylate Calcium 5’-inosinate Assay Not less than 97% and not more than the equivalent of 102% of C10H11CaN4O8P and C10H12CaN5O8P, calculated on the anhydrous basis. The proportion of C10H11CaN4O8P or C10H12CaN5O8P to the sum of them is between 47% and 53%. DESCRIPTION Odourless, white or off-white crystals or powder FUNCTIONAL USES Flavour enhancer CHARACTERISTICS IDENTIFICATION Solubility (Vol. 4) Sparingly soluble in water Test for ribose (Vol. 4) Passes test Test for organic phosphate Passes test (Vol. 4) Test 5 ml of a 1 in 2,000 solution Test for inosinic acid To 2 ml of a 1 in 2,000 solution add 2 ml of 10% hydrochloric acid and 0.1 g of zinc powder, heat in a water bath for 10 min, and filter. Cool the filtrate in ice water, add 1 ml of a 3 in 1,000 sodium nitrite solution, shake well, and allow to stand for 10 min. Add 1 ml of a 1 in 200 ammonium sulfamate solution, shake well, and allow to stand for 5 min. Add 1 ml of a 1 in 500 N-(1- naphthyl)-ethylenediamine dihydrochloride solution.
    [Show full text]
  • Eosinophilic Fasciitis (Shulman Syndrome)
    CONTINUING MEDICAL EDUCATION Eosinophilic Fasciitis (Shulman Syndrome) Sueli Carneiro, MD, PhD; Arles Brotas, MD; Fabrício Lamy, MD; Flávia Lisboa, MD; Eduardo Lago, MD; David Azulay, MD; Tulia Cuzzi, MD, PhD; Marcia Ramos-e-Silva, MD, PhD GOAL To understand eosinophilic fasciitis to better manage patients with the condition OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Recognize the clinical presentation of eosinophilic fasciitis. 2. Discuss the histologic findings in patients with eosinophilic fasciitis. 3. Differentiate eosinophilic fasciitis from similarly presenting conditions. CME Test on page 215. This article has been peer reviewed and is accredited by the ACCME to provide continuing approved by Michael Fisher, MD, Professor of medical education for physicians. Medicine, Albert Einstein College of Medicine. Albert Einstein College of Medicine designates Review date: March 2005. this educational activity for a maximum of 1 This activity has been planned and implemented category 1 credit toward the AMA Physician’s in accordance with the Essential Areas and Policies Recognition Award. Each physician should of the Accreditation Council for Continuing Medical claim only that credit that he/she actually spent Education through the joint sponsorship of Albert in the activity. Einstein College of Medicine and Quadrant This activity has been planned and produced in HealthCom, Inc. Albert Einstein College of Medicine accordance with ACCME Essentials. Drs. Carneiro, Brotas, Lamy, Lisboa, Lago, Azulay, Cuzzi, and Ramos-e-Silva report no conflict of interest. The authors report no discussion of off-label use. Dr. Fisher reports no conflict of interest. We present a case of eosinophilic fasciitis, or Shulman syndrome apart from all other sclero- Shulman syndrome, in a 35-year-old man and dermiform states.
    [Show full text]
  • Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells
    Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells William N. Kelley, James B. Wyngaarden J Clin Invest. 1970;49(3):602-609. https://doi.org/10.1172/JCI106271. Research Article In the present study we have examined the effects of allopurinol and oxipurinol on thed e novo synthesis of purines in cultured human fibroblasts. Allopurinol inhibits de novo purine synthesis in the absence of xanthine oxidase. Inhibition at lower concentrations of the drug requires the presence of hypoxanthine-guanine phosphoribosyltransferase as it does in vivo. Although this suggests that the inhibitory effect of allopurinol at least at the lower concentrations tested is a consequence of its conversion to the ribonucleotide form in human cells, the nucleotide derivative could not be demonstrated. Several possible indirect consequences of such a conversion were also sought. There was no evidence that allopurinol was further utilized in the synthesis of nucleic acids in these cultured human cells and no effect of either allopurinol or oxipurinol on the long-term survival of human cells in vitro could be demonstrated. At higher concentrations, both allopurinol and oxipurinol inhibit the early steps ofd e novo purine synthesis in the absence of either xanthine oxidase or hypoxanthine-guanine phosphoribosyltransferase. This indicates that at higher drug concentrations, inhibition is occurring by some mechanism other than those previously postulated. Find the latest version: https://jci.me/106271/pdf Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells WILLIAM N. KELLEY and JAMES B. WYNGAARDEN From the Division of Metabolic and Genetic Diseases, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27706 A B S TR A C T In the present study we have examined the de novo synthesis of purines in many patients.
    [Show full text]
  • Alternative Pathways of Glucose Metabolism II. Nucleotides from The
    Alternative Pathways of Glucose Metabolism II . Nucleotides from the Acid-soluble Fraction of Normal and Tumor Tissues and Studies on Nucleic Acid Synthesis in Tumors*t HANNS SCHMITZ4 VAN R. POTTER, ROBERT B. HTJRLBERT,@ AND DWAIN M. WHITE (McArdie Memovial Laboratory, the Medical School, University of Wisconain, Madison, WI..) The first paper (18) in this series on the alterna MATERIALS AND METHODS tive pathways of glucose metabolism established The present study has involved the measure the fact that radioactivity from glucose-i-C'4 was ment of the specific activities of the free 5' mono-, readily incorporated into the pentose moiety of the di-, and triphosphates of adenosine, guanosine, ribonucleic and desoxyribonucleic acids of Flexner cytidine, and uridine from the acid-soluble extract Jobling tumors in rats, and described the over-all of tumor tissue in relation to the specific activities distribution of radioactivity in the acid-soluble of the corresponding nucleotides that were oh and acid-insoluble fractions of tumor and liver tis tamed by chemical or enzymatic hydrolysis of the sue at various time periods. The acid-soluble frac nucleic acids from the same tissue samples, at tion of tissue contains an appreciable amount of specified time intervals after the injection of glu free nucleotides which are possible intermediary cose-1-C'4. The experimental plan corresponds compounds in the synthesis of the nucleic acids exactly to that described in the preceding paper; (6, 7, 8, 9, 13, 16). It was noted (18) that as the C'4 many of
    [Show full text]